Estimated Incidence of Respiratory Syncytial Virus (RSV)-related Hospitalizations for Acute Respiratory Infections (ARIs), including Community Acquired Pneumonia (CAP), in Adults in Germany
Caihua Liang,Elizabeth Begier,Stefan Hagel,Juliane Ankert,Liz Wang,Claudia Schwarz,Lea J. Bayer,Christof von Eiff,Qing Liu,Jo Southern,Jeffrey Vietri,Sonal Uppal,Bradford D. Gessner,Christian Theilacker,Mathias Pletz
DOI: https://doi.org/10.1101/2024.06.09.24308507
2024-06-11
Abstract:Background: RSV is a leading cause of ARI, including CAP, in older adults, but available data often substantially underestimate incidence. We estimated RSV-related ARI hospitalization incidence from a prospective CAP study and adjusted for undiagnosed RSV infections due to use of nasopharyngeal/nasal swab testing only.
Methods: We conducted active, population-based surveillance of adult CAP hospitalizations in Thuringia (Germany) between 2021-2023. Participant nasopharyngeal/nasal swabs were RSV-tested by multiplex nucleic acid amplification testing. To estimate RSV-related CAP incidence, age-group specific proportions of RSV positivity among tested patients were applied to all-cause CAP incidence. To adjust for underdiagnosis due to nasopharyngeal/nasal swab sampling only and the percentage of ARI with pneumonia diagnoses, we used data from a large, prospective, multispecimen study assessing impact of collecting multiple specimens (nasopharyngeal/nasal swab, saliva, paired serology, and sputum) among 3,669 adults hospitalized for ARI.
Results: Among 1,040 enrolled adults (≥18 years) with radiologically confirmed CAP, 38 tested RSV-positive via nasopharyngeal/nasal swab (3.7%). The percentage positive increased to 7.8% after adjusting for higher RSV detection with multiple specimens compared to nasopharyngeal/nasal swab only. Adjusted RSV-related CAP hospitalization rates were 4.7 (95%CI 1.5-11.2) and 109.1 (95%CI 89.6-131.6) per 100,000 adults aged 18-59 and >=60 years, respectively. Adjusted incidences of RSV-related ARI were 18.4 (95%CI 11.0-28.9) and 377.6 (95%CI 340.5-417.7) per 100,000 adults aged 18-59 and >=60 years, respectively. Among RSV-positive CAP hospitalizations, 12.1% of patients aged >=65 years died within 30 days, with no deaths in those aged 18-64 years. Cardiovascular events occurred in 11.1% of patients aged 18-64 and 36.4% of those aged >=65 years.
Conclusions: Older adults in Germany face a high burden of RSV-related ARI hospitalizations, including CAP, underscoring the potential utility of RSV vaccination for this population.
Epidemiology